{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:02:49Z","timestamp":1782975769553,"version":"3.54.5"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Glob. Women\u2019s Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dyslipidemia is a prevalent metabolic disorder in breast cancer patients and an important comorbidity that impacts cardiovascular outcomes, treatment tolerance, and long-term prognosis. It may also be linked to tumor progression, yet the distribution characteristics of lipid abnormalities, especially their heterogeneity across different clinical stages and molecular subtypes of breast cancer, remain insufficiently characterized in existing research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study was conducted at the Affiliated Zhongshan Hospital of Dalian University, enrolling 5,246 patients with pathologically confirmed primary breast cancer diagnosed from 2014 to 2024 with complete clinical staging and fasting lipid profile data. Dyslipidemia was defined as at least one abnormal lipid parameter (LDL-C\u2009\u2265\u20093.4\u2005mmol\/L, HDL-C\u2009&amp;lt;\u20091.0\u2005mmol\/L, TC\u2009\u2265\u20095.2\u2005mmol\/L, TG\u2009\u2265\u20091.7\u2005mmol\/L). Stage-stratified multivariable logistic regression analyses were used to identify independent associated factors, with subtype-based subgroup analyses and sensitivity analyses excluding CHD patients performed to verify result robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dyslipidemia affected 54.8%\u201371.9% of patients across all clinical stages, with TC and TG abnormalities being the most common, followed by reduced HDL-C and elevated LDL-C. Cumulative proportions of individual lipid abnormalities exceeded 100% per stage, indicating frequent coexistence of multiple abnormalities. Obvious subtype heterogeneity was observed: Luminal B (HER\u2013) had low early-stage HDL-C reduction, while triple-negative patients had a markedly high LDL-C elevation rate (up to 50%) in stage IV. Tumor burden-related factors and selected molecular pathology indicators were independently associated with dyslipidemia in a stage-specific manner, and CHD exclusion did not alter the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dyslipidemia is a pervasive and heterogeneous metabolic comorbidity in breast cancer, with distinct stage- and subtype-specific patterns closely linked to tumor burden and molecular biological characteristics. Routine lipid assessment and subtype-tailored metabolic management should be integrated as an essential component into the comprehensive clinical care of breast cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgwh.2026.1845647","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:33:26Z","timestamp":1782970406000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Distribution characteristics and associated factors of dyslipidemia across clinical stages of breast cancer: a retrospective observational study"],"prefix":"10.3389","volume":"7","author":[{"given":"Zechang","family":"Xin","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pisong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongbin","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningxin","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiting","family":"Yu","sequence":"additional","affiliation":[{"name":"Central Laboratory, Affiliated Zhongshan Hospital of Dalian University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1007\/s12672-025-03180-0","article-title":"Recent strategies in diagnosis, screening, prevention, and treatment of breast cancer in young women","volume":"16","author":"Sharma","year":"2025","journal-title":"Discov Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1587517","DOI":"10.3389\/fonc.2025.1587517","article-title":"Advances in breast cancer diagnosis: a comprehensive review of imaging, biosensors, and emerging wearable technologies","volume":"15","author":"Khan","year":"2025","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s40001-024-01802-x","article-title":"Dyslipidemia and associated factors among adult cardiac patients: a hospital-based comparative cross-sectional study","volume":"29","author":"Abera","year":"2024","journal-title":"Eur J Med Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1506149","DOI":"10.3389\/fcvm.2025.1506149","article-title":"Call for a consensual definition of dyslipidemia in coronary angiography trials","volume":"12","author":"Clerc","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.1038\/s41598-021-86336-6","article-title":"Association of baseline as well as change in lipid levels with the risk of cardiovascular diseases and all-cause deaths","volume":"11","author":"Hsu","year":"2021","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mco2.27","article-title":"Lipid metabolism in cancer progression and therapeutic strategies","volume":"2","author":"Fu","year":"2021","journal-title":"MedComm"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e20201606","DOI":"10.1084\/jem.20201606","article-title":"Lipid metabolism and cancer","volume":"218","author":"Bian","year":"2021","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"101376","DOI":"10.1016\/j.gendis.2024.101376","article-title":"Lipid metabolism involved in progression and drug resistance of breast cancer","volume":"12","author":"Fu","year":"2025","journal-title":"Genes Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3390\/life15050689","article-title":"Lipid metabolism and breast cancer: a narrative review of the prognostic implications and chemotherapy-induced dyslipidemia","volume":"15","author":"Faur","year":"2025","journal-title":"Life"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocr Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11909\/j.issn.1671-5411.2018.01.011","article-title":"2016 Chinese guidelines for the management of dyslipidemia in adults","volume":"15","author":"Jun-Ren","year":"2018","journal-title":"J Geriatr Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1579423","DOI":"10.3389\/fonc.2025.1579423","article-title":"Unveiling the impact of lipid metabolism on triple-negative breast cancer growth and treatment options","volume":"15","author":"Cai","year":"2025","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.7150\/ijbs.92125","article-title":"Reprogramming of lipid metabolism mediates crosstalk, remodeling, and intervention of microenvironment components in breast cancer","volume":"20","author":"Wang","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/cancers17040650","article-title":"Lipid metabolism in breast cancer: from basic research to clinical application","volume":"17","author":"Huang","year":"2025","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.devcel.2021.04.013","article-title":"Lipid metabolism in cancer: new perspectives and emerging mechanisms","volume":"56","author":"Broadfield","year":"2021","journal-title":"Dev Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"577420","DOI":"10.3389\/fonc.2020.577420","article-title":"Alterations of lipid metabolism in cancer: implications in prognosis and treatment","volume":"10","author":"Fern\u00e1ndez","year":"2020","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jncc.2024.11.001","article-title":"Unraveling molecular interconnections and identifying potential therapeutic targets of significance in obesity-cancer link","volume":"5","author":"Abdulla","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"B20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12964-023-01178-1","article-title":"The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape","volume":"21","author":"Zipinotti Dos Santos","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1158\/0008-5472.CAN-23-3966","article-title":"Estrogen induces LCAT to maintain cholesterol homeostasis and suppress hepatocellular carcinoma development","volume":"84","author":"He","year":"2024","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jshs.2023.07.001","article-title":"Comparison of the effects of high-intensity interval and moderate-intensity continuous training on inflammatory markers, cardiorespiratory fitness, and quality of life in breast cancer patients","volume":"12","author":"Isanejad","year":"2023","journal-title":"J Sport Health Sci"}],"container-title":["Frontiers in Global Women's Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgwh.2026.1845647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:33:28Z","timestamp":1782970408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgwh.2026.1845647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":22,"alternative-id":["10.3389\/fgwh.2026.1845647"],"URL":"https:\/\/doi.org\/10.3389\/fgwh.2026.1845647","relation":{},"ISSN":["2673-5059"],"issn-type":[{"value":"2673-5059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1845647"}}